Next Article in Journal
Phospholipids are A Potentially Important Source of Tissue Biomarkers for Hepatocellular Carcinoma: Results of a Pilot Study Involving Targeted Metabolomics
Previous Article in Journal
Breast Cancer Diagnosis Using an Efficient CAD System Based on Multiple Classifiers
Previous Article in Special Issue
Glycan Analysis as Biomarkers for Testicular Cancer
Open AccessArticle

Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature

1
Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
2
Cancer Prevention in the Pacific Program University of Hawaii Cancer Center, Honolulu, HI 96813, USA
3
Translational and Clinical Research Program University of Hawaii Cancer Center, Honolulu, HI 96813, USA
4
Department of Urology, Kyoto University, Kyoto 606-8507, Japan
*
Author to whom correspondence should be addressed.
Diagnostics 2019, 9(4), 166; https://doi.org/10.3390/diagnostics9040166
Received: 26 September 2019 / Revised: 18 October 2019 / Accepted: 19 October 2019 / Published: 29 October 2019
(This article belongs to the Special Issue Urogenital Cancers: Diagnostic, Predictive, and Prognostic Markers)
The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer). Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer. The concentrations of the 10 proteins (A1AT; apolipoprotein E—APOE; angiogenin—ANG; carbonic anhydrase 9—CA9; interleukin 8—IL-8; matrix metalloproteinase 9—MMP-9; matrix metalloproteinase 10—MMP10; plasminogen activator inhibitor 1—PAI-1; syndecan—SDC1; and vascular endothelial growth factor—VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s technical specifications. The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA). The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens. View Full-Text
Keywords: biomarkers; bladder cancer; multiplex; protein; urine biomarkers; bladder cancer; multiplex; protein; urine
Show Figures

Figure 1

MDPI and ACS Style

Furuya, H.; Pagano, I.; Chee, K.; Kobayashi, T.; Wong, R.S.; Lee, R.; Rosser, C.J. Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature. Diagnostics 2019, 9, 166.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop